

**Table S1.** Correlation between OCT parameters and disease severity, disease duration and visual function

	Macula		RNFL				
	Average	Foveal	Average	Superior	Nasal	Inferior	Temporal
<b>SARA</b>	r(47)=-0.320	r(45)=0.080	r(38)=-0.56	r(38)=-0.42	r(38)= -0.308	r(38)=-0.520	r(38)=-0.399
	<b>p=0.03</b>	p=0.6	<b>p=0.0002</b>	<b>p=0.008</b>	p=0.06	<b>p=0.0008</b>	<b>p=0.01</b>
<b>Disease</b>	rs = -0.286	rs = -0.259	rs = -0.266	rs = -0.165	rs = -0.057	rs = -0.195	rs = -0.137
<b>duration</b>	p=0.051	p=0.09	p=0.1	p=0.3	p=0.7	p=0.2	p=0.4
<b>BCVA</b>	r(47)= -0.391	r(45)=-0.015	r(38)=-0.396	r(38)=-0.292	r(38)= -0.089	r(38)=-0.44	r(38)=-0.374
	<b>p=0.006</b>	p=0.9	<b>p=0.01</b>	p=0.08	p=0.6	<b>p=0.005</b>	<b>p=0.02</b>

Numbers in bold p-value &lt; 0.05.

**Table S2.** Baseline, follow-up and expected follow-up RNFL thickness in FRDA patients.

Patient	Baseline RNFL thickness	Follow up RNFL thickness	Expected Follow Up RNFL thickness *	Difference	Time from baseline(months)
2	94	93	93.67	0.33	12
3	114	106.5	113.37	6.87	23
4	81	80	80.175	0.18	30
5	74	73	73.175	0.18	30
6	94	93	93.67	0.33	33
7	108	106	107.37	1.37	23
10	104	90.5	103.37	12.87	23
15	55	44	54.2	10.2	29
18	107	103	105.68	2.68	48
21	81	72.5	80.18	7.68	30
23	74	66	73.2	7.18	30
25	97	95.5	96.18	0.68	30
33	90.5	90	90.12	0.12	14
34	96	94	95.56	1.56	16
36	87	85.5	86.15	0.65	31
37	76	67	75.18	8.18	30
42	83	82.5	82.1	-	33
43	84.5	83	83.73	0.73	28
44	88	86.5	87.23	0.73	28

\* Minimal thinning reported in healthy subjects (0.33  $\mu\text{m}/\text{year}$ ).